News
Stocktwits on MSN1d
HC Wainwright Doubles Price Target On Insmed After Brinsupri Approval: Retail Expects Stock To Hit $150 By End Of Week
H.C. Wainwright on Wednesday doubled its price target on Insmed (INSM) to $240 from $120 while keeping a ‘Buy’ rating on the ...
With a landmark U.S. approval Tuesday, Insmed is making waves with a new class of drug that’s also the first to be green lit in the chronic lung disease bronchiectasis. | The FDA on Tuesday signed ...
Insmed has won U.S. Food and Drug Administration approval of Brinsupri as the first and only treatment for the chronic lung disease non-cystic fibrosis bronchiectasis. Insmed on Tuesday said the FDA ...
Maxor Specialty Pharmacy, a VytlOne company, was selected by Insmed to be a limited distribution provider of Brinsupri™. Brinsupri is a dipeptidyl peptidase 1 (DPP1) inhibitor indicated for the ...
After Insmed (INSM) announced the FDA approved brensocatib as “Brinsupri,” making it the first approved treatment for non-cystic fibrosis ...
Hosted on MSN2d
Insmed price target raised to $138 from $120 at RBC Capital
After Insmed (INSM) announced the FDA approved Brinsupri for non-cystic fibrosis bronchiectasis, RBC Capital raised the firm’s price target on Insmed to $138 from $120 and keeps an Outperform ...
PANTHERx® Rare Pharmacy, a leader in rare disease product patient access and support services in the United States, announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback